Switch theme
Sign up to access all valuation multiples
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
2018
72
LTM Revenue $5.6M
LTM EBITDA -$43.2M
$178M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lucid Diagnostics has a last 12-month revenue of $5.6M and a last 12-month EBITDA of -$43.2M.
In the most recent fiscal year, Lucid Diagnostics achieved revenue of $4.3M and an EBITDA of -$44.3M.
Lucid Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lucid Diagnostics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.4M | $4.3M | XXX | XXX | XXX |
| Gross Profit | -$3.2M | -$3.6M | XXX | XXX | XXX |
| Gross Margin | -133% | -82% | XXX | XXX | XXX |
| EBITDA | -$49.8M | -$44.3M | XXX | XXX | XXX |
| EBITDA Margin | -2049% | -1020% | XXX | XXX | XXX |
| Net Profit | -$56.2M | -$52.7M | XXX | XXX | XXX |
| Net Margin | -2313% | -1212% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lucid Diagnostics's stock price is $1.
Lucid Diagnostics has current market cap of $125M, and EV of $178M.
See Lucid Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $178M | $125M | XXX | XXX | XXX | XXX | $-0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lucid Diagnostics has market cap of $125M and EV of $178M.
Lucid Diagnostics's trades at 31.6x LTM EV/Revenue multiple, and -4.1x LTM EBITDA.
Analysts estimate Lucid Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lucid Diagnostics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $178M | XXX | XXX | XXX |
| EV/Revenue | 41.1x | XXX | XXX | XXX |
| EV/EBITDA | -4.0x | XXX | XXX | XXX |
| P/E | -2.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLucid Diagnostics's NTM/LTM revenue growth is 161%
Lucid Diagnostics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Lucid Diagnostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lucid Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lucid Diagnostics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 79% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1020% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -859% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 379% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 464% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 138% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 996% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lucid Diagnostics acquired XXX companies to date.
Last acquisition by Lucid Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Lucid Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lucid Diagnostics founded? | Lucid Diagnostics was founded in 2018. |
| Where is Lucid Diagnostics headquartered? | Lucid Diagnostics is headquartered in United States of America. |
| How many employees does Lucid Diagnostics have? | As of today, Lucid Diagnostics has 72 employees. |
| Who is the CEO of Lucid Diagnostics? | Lucid Diagnostics's CEO is Dr. Lishan Aklog, M.D.. |
| Is Lucid Diagnostics publicy listed? | Yes, Lucid Diagnostics is a public company listed on NAS. |
| What is the stock symbol of Lucid Diagnostics? | Lucid Diagnostics trades under LUCD ticker. |
| When did Lucid Diagnostics go public? | Lucid Diagnostics went public in 2021. |
| Who are competitors of Lucid Diagnostics? | Similar companies to Lucid Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Lucid Diagnostics? | Lucid Diagnostics's current market cap is $125M |
| What is the current revenue of Lucid Diagnostics? | Lucid Diagnostics's last 12-month revenue is $5.6M. |
| What is the current EBITDA of Lucid Diagnostics? | Lucid Diagnostics's last 12-month EBITDA is -$43.2M. |
| What is the current EV/Revenue multiple of Lucid Diagnostics? | Current revenue multiple of Lucid Diagnostics is 31.6x. |
| What is the current EV/EBITDA multiple of Lucid Diagnostics? | Current EBITDA multiple of Lucid Diagnostics is -4.1x. |
| What is the current revenue growth of Lucid Diagnostics? | Lucid Diagnostics revenue growth between 2023 and 2024 was 79%. |
| Is Lucid Diagnostics profitable? | Yes, Lucid Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
